In a retrospective analysis, researchers from the Moffitt Cancer Center in Tampa, FL, reported that the treatment margins enabled by adaptation, real-time tracking, and automated beam control on MRIdian SMART may enable ablative radiation to be performed with minimal toxicity in hard-to-treat, metastatic, primary ultracentral and central lung lesions, according to the vendor.